Krys­tal Biotech rais­es $160M via PIPE on heels of FDA ap­proval for gene ther­a­py

Krys­tal Biotech has re­ceived $160 mil­lion in pri­vate fi­nanc­ing days af­ter the FDA ap­proved Vyju­vek, a gene ther­a­py for chil­dren with a rare skin dis­ease called dy­s­troph­ic epi­der­mol­y­sis bul­losa, and Krys­tal’s first-ever ap­proved treat­ment.

On Mon­day, the com­pa­ny an­nounced it is sell­ing more than 1.7 mil­lion shares at $92.50 a pop, a slight de­cline over Fri­day’s clos­ing price of $96.06 a share. Avoro Cap­i­tal Ad­vi­sors and Red­mile Group led the fi­nanc­ing, with Braid­well LP and Fra­zier Life Sci­ences al­so pitch­ing in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER